Top

Published in:

Open Access 01-11-2010 | Poster presentation

Mycophenolate mofetil use in refractory juvenile systemic lupus erythematosus

Authors: R Marques, C Ponte, J E Fonseca, J Pereira, A Rodrigues, C Macieira, R Stone, C Simão, M Almeida, H Canhão, F Ramos, J Á Pereira da Silva

Published in: Journal of Translational Medicine | Special Issue 1/2010

Excerpt

The optimal immunosuppressive treatment in patients with systemic lupus erythematosus (SLE) remains controversial [1]. Mycophenolate mofetil (MMF) has proved to be an efficacious and safe therapy in adult lupus nephritis [2]. Recently, this drug has been suggested as a possible new alternative treatment for juvenile-SLE, especially in cases of lupus nephritis refractory to treatment with corticosteroids, cyclophosphamide azathioprine, methotrexate and/or cyclosporine [3-4]. In this review we describe our experience with six children diagnosed with SLE and treated with MMF. …

Pereira J, Ferreira F, Rodrigues AM: Rituximab Use in Pediatric Autoimmune Diseases Four Case Reports. Ann N Y Acad Sci. 2009, 1-9.

Fujinaga S: Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. 2008, 23 (10): 1877-82. Epub

Marks SD, Tullus K: Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr. 2010, Mar 11

Dittrich K: Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus. Klin Padiatr. 2009, 221 (7): 425-9. 10.1055/s-0029-1234130.CrossRefPubMed

Title: Mycophenolate mofetil use in refractory juvenile systemic lupus erythematosus
Authors: R Marques
C Ponte
J E Fonseca
J Pereira
A Rodrigues
C Macieira
R Stone
C Simão
M Almeida
H Canhão
F Ramos
J Á Pereira da Silva
Publication date: 01-11-2010
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue Special Issue 1/2010
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-8-S1-P73

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Mycophenolate mofetil use in refractory juvenile systemic lupus erythematosus

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Cytokine pattern in very early rheumatoid arthritis favours B cell activation and survival

Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with Systemic Sclerosis and do not influence gene expression

Spondyloarthropathy and rheumatoid arthritis: two different diseases, a similar cytokine network

Functional relevance of a non-synonymous substitution in the CD5 gene (V471A) targeted for positive selection in East Asian populations

Single-cell gene profiling analysis of human regulatory T cell subsets

Patients with non-relapsing ANCA-associated vasculitis have increased numbers of circulating IL-10 producing Th17 cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page